RO5509554

Hoffmann-La Roche · Phase 1 active Small molecule

At a glance

Generic name	RO5509554
Also known as	RG7155
Sponsor	Hoffmann-La Roche
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors (PHASE1)
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors (PHASE1)
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RO5509554 CI brief — competitive landscape report
RO5509554 updates RSS · CI watch RSS
Hoffmann-La Roche portfolio CI